Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.725 USD | +0.75% | +28.31% | +75.28% |
May. 07 | Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral | MT |
Mar. 20 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Evolution of the average Target Price on Design Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Design Therapeutics, Inc.
Piper Sandler | |
RBC Capital Markets | |
Wedbush | |
SVB Securities LLC | |
Goldman Sachs | |
SVB Leerink |
EPS Revisions
- Stock Market
- Equities
- DSGN Stock
- Consensus Design Therapeutics, Inc.